Keywords: Narcolepsy treatments, Opportunities, GlabalData, UCB, Xyrem, Bioproject, BF2.649, Cephalon, Provigil, Nuvigil

Opportunities for Pharma in narcolepsy

Article | 20 February 2012

The narcolepsy therapeutics developmental pipeline is weak, with only six molecules in development, providing opportunities for drugs companies to expand ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Bioproject

Cephalon

UCB

Teva Pharmaceutical Industries

Go to company listing

Related Drugs

Provigil

Nuvigil

Xyrem

Go to drug listing